<DOC>
	<DOCNO>NCT00202839</DOCNO>
	<brief_summary>This open-label , randomize , comparative , multicenter , 48-week study design evaluate efficacy safety combination treatment pegylated interferon ribavirin adult subject diagnosis compensate chronic hepatitis C ( hepatitis C virus ( HCV ) -ribonucleic acid ( RNA ) positive ) ( Genotype 1 ) . All subject complete 24 week treatment , term Pilot Treatment Program , eligible subject randomly assign one two study group . One group follow additional 48 week without study medication , continuously treat additional 24 week follow another 24 week without study medication . Sustained virologic response , define undetectable HCV-RNA serum end follow-up period , measure along outcome .</brief_summary>
	<brief_title>Peg-Intron/Ribavirin G 1 HCV Non-Extended Versus 24 Week Extended Treatment After 24 Weeks ( Study P04144 ) ( COMPLETED )</brief_title>
	<detailed_description>This open-label , randomize , comparative , multicenter study evaluation PegIntron/Ribavirin therapy efficacy safety adult subject diagnosis compensate chronic hepatitis C ( HCV-RNA+ ) ( Genotype 1 ) . This 48-week study , subject participate Pilot Treatment Program complete 24 week treatment . To avoid treatment gap , subject screen eligible subject sign inform consent prior end Pilot Treatment Program . After completion Pilot Treatment Program , eligible subject randomly assign either study group . Subjects 24-Week Treatment arm followed-up without study medication 48 week ; subject 48-Week Treatment arm continuously treat another 24 week subject 48-Week Treatment arm follow another 24 week completion treatment period . Subjects arm evaluate screening , randomization , 4 , 8 , 12 , 16 , 20 , 24 , 28 , 36 48 week randomization .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Subject must willing give write informed consent able adhere dose visit schedule . Males nonpregnant female age &gt; = 18 year , subject 65 year age must generally good health must discuss approve principal investigator prior entry . The laboratory evaluation within 6 month prior enter Pilot Treatment Program must meet following criterion : Hemoglobin value &gt; = 12 g/dL female &gt; = 13 g/dL male Neutrophil count &gt; = 1.5 X10^9/L Platelets count &gt; = 100 x 10^9/L Total bilirubin &lt; 1.5 mg/dL Serum creatinine within normal limit Positive serum HCVRNA ( &gt; = 50 IU ( 100 copy number ) /mL ) AntiHCV positive Available HCV genotype 1 Liver biopsy perform within 12 month prior entry protocol pathology report confirm histological diagnosis consistent chronic hepatitis ( METAVIR system &gt; =F1 ) . Compensated liver disease follow hematological , biochemical , serologic criterion screen visit : Hemoglobin value &gt; = 9 g/dL Neutrophil count &gt; = 0.75 x 10^9/L Platelets count &gt; = 50 x 10^9/L Prothrombin time ( PT ) prolong &lt; = 3 sec , International Normalized Ratio ( INR ) &lt; = 1.2 Total bilirubin &lt; = 3 mg/dL Within normal limit ( subject require medication maintain TSH level normal range eligible inclusion/exclusion criterion meet ) . AntiHuman Immunodeficiency Virus ( HIV ) negative . Alphafetoprotein ( AFP ) value within normal limit obtain within 12 month prior entry . Results upper limit normal &lt; = 50 ng/mL require following : AFP value &lt; = 50 ng/mL obtain within 9 month prior entry study Screening period , Ultrasound obtain within 9 month prior entry screen period study evidence hepatocellular carcinoma . A urine pregnancy test obtain prior initiation pilot treatment must negative . Female subject must breast feeding . Reconfirmation sexuallyactive subject practice acceptable method contraception screen period . Complete 24 week treatment Pilot Treatment Program PegIntron + Ribavirin . Must never treat interferon HCV infect hepatitis ( treatment na√Øve ) Pilot Treatment Program . The total amount PegIntron Ribavirin receive pilot treatment program must achieve 80 % recommended dosage . Women pregnant nursing . Have decompensated cirrhosis . History severe psychiatric disease , especially depression . Concurrent malignancy ( include hepatocellular carcinoma ) . Unstable significant cardiovascular disease . Subjects ( ECG ) show clinically significant abnormality . Prolonged exposure know hepatotoxin alcohol drug . History thyroid disease poorly control prescribed medication . Poorly control diabetes mellitus . Has suspect confirm significant hepatic disease etiology HCV . Patients coinfected hepatitis B /or human immunodeficiency virus ( HIV ) . Severe renal disease myeloid dysfunction . History organ transplantation cornea hair transplant . Any medical condition requiring , likely require course study , chronic systemic administration steroid . Any condition opinion investigator would make subject unsuitable enrollment , could interfere subject participate complete protocol . Allergy interferon .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>